Exbio — Research products — Antibodies — Other intracellular antigens — Anti-LARGE1 Purified

Anti-LARGE1 Purified

Regulatory status

RUO

Antigen

LARGE1

Clone

LARGE-02

Format

Purified

Reactivity

Human

Application

WB, FC (QC tested)

Variant

0.1 mg

11-702-C100

In stock

203.50 USD

0.025 mg

11-702-C025

Delivery 1 week

101.75 USD

Variant

0.1 mg

11-702-C100

In stock

203.50 USD

0.025 mg

11-702-C025

Delivery 1 week

101.75 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2b

Specificity

The mouse monoclonal antibody LARGE-02 recognizes human LARGE1, a glycosyltransferase expressed mainly in the Golgi apparatus. Crossreactivity with LARGE2 was not determined.

Application

WB, FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1-5 μg/ml. Intracellular staining.

Reactivity

Human

Immunogen

Recombinant fragment of human LARGE1 (amino acids 35-142)

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

Xysosyl- and glucosyl transferase 1

Antigen description

LARGE1 serves as a glycosyltransferase which participates in glycosylation of the muscle membrane protein alpha-dystroglycan. Mutations of LARGE1 lead to hypoglycosylation of alpha-dystroglycan and cause congenital muscular dystrophy (MDC1D) associated with severe mental retardation. Altered alpha-dystroglycan glycosylation may also play a role in cancer, as hypoglycosylation of the protein and loss of laminin binding have been demonstrated in invasive carcinoma cells.

Entrez Gene ID 9215

UniProt ID O95461

Separation of Hek293 cells transfected with LARGE1 vector and stained using anti-LARGE1 (LARGE-02) purified antibody (concentration in sample 15 μg/ml, GAM APC, red-filled) from Hek293 cells transfected with LARGE1 and unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (intracellular staining).

General references:

Grewal PK, McLaughlan JM, Moore CJ, Browning CA, Hewitt JE: Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Glycobiology. 2005 Oct;15(10):912-23.
PubMed